Anacor
Anacor Pharmaceuticals
Type | Public |
---|---|
Key people | Paul L. Berns (CEO) |
Industry | Pharmaceuticals |
Products | Tavaborole, Crisaborole |
Website | [www.anacor.com Official website] |
Anacor Pharmaceuticals was a biopharmaceutical company that focused on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded in 2002 and was headquartered in Palo Alto, California.
History[edit | edit source]
Anacor was founded by David Perry in 2002. The company initially focused on developing boron-based compounds for the treatment of infectious and inflammatory diseases. Anacor's proprietary boron chemistry platform allowed for the creation of unique small molecules with potential therapeutic benefits.
In 2016, Anacor was acquired by Pfizer for approximately $5.2 billion. This acquisition was primarily driven by the potential of Anacor's lead product, crisaborole, a topical treatment for atopic dermatitis.
Products[edit | edit source]
Anacor developed several products, with its most notable being:
- Tavaborole (Kerydin): An antifungal medication used to treat onychomycosis, a fungal infection of the toenails. Tavaborole was approved by the U.S. Food and Drug Administration (FDA) in 2014.
- Crisaborole (Eucrisa): A non-steroidal topical anti-inflammatory medication used for the treatment of mild to moderate atopic dermatitis. Crisaborole was approved by the FDA in 2016 and was a significant factor in Pfizer's acquisition of Anacor.
Boron Chemistry Platform[edit | edit source]
Anacor's unique approach to drug development was centered around its boron chemistry platform. Boron is a versatile element that can form stable covalent bonds with carbon, nitrogen, and oxygen, allowing for the creation of novel chemical structures. This platform enabled Anacor to develop small molecules with unique properties that could potentially address unmet medical needs.
Acquisition by Pfizer[edit | edit source]
In May 2016, Pfizer announced its acquisition of Anacor Pharmaceuticals for $5.2 billion. The acquisition was completed in June 2016. This strategic move was aimed at strengthening Pfizer's inflammation and immunology portfolio, particularly with the addition of crisaborole.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD